Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclatasvir plus Sofosbuvir effects on angiogenesis in chronic HCV
NCT03646396Recruiting
- Start
- Aug 2018
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of daclatasvir and sofosbuvir in hepatitis C (HCV). Primary endpoints: Vascular Endothelial Growth Factor at 6 months and Transforming Growth Factor Beta 1 at 6 months. Started Aug 2018; status: recruiting.
02
Drugs
daclatasvirsofosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03646396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646396.